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Accepted 20 June 2012; Published online 24 November 2012AbstractObjectives: Indirect comparison methods have been increasingly used to assess the effectiveness of different interventions compara-
tively. This study evaluated a Trial Similarity and Evidence Consistency Assessment (TSECA) framework for assessing key assumptions
underlying the validity of indirect comparisons.
Study Design and Setting: We applied the TSECA framework to 94 Cochrane Systematic Reviews that provided data to compare two
interventions by both direct and indirect comparisons. Using the TSECA framework, two reviewers independently assessed and scored trial
similarity and evidence consistency. A detailed case study provided further insight into the usefulness and limitations of the framework
proposed.
Results: Trial similarity and evidence consistency scores obtained using the assessment framework were not associated with statisti-
cally significant inconsistency between direct and indirect estimates. The case study illustrated that the assessment framework could be
used to identify potentially important differences in participants, interventions, and outcome measures between different sets of trials in
the indirect comparison.
Conclusion: Although the overall trial similarity and evidence consistency scores are unlikely to be sufficiently accurate for predicting
inconsistency between direct and indirect estimates, the assessment framework proposed in this study can be a useful tool for identifying
between-trial differences that may threaten the validity of indirect treatment comparisons.
 2013 Elsevier Inc.
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Open access under CC BY license. 1. Introduction
The use of indirect comparisons for evaluating compar-
ative effectiveness of different treatments has greatly in-
creased [1,2]. Simple and complex statistical methods
have been developed to make indirect treatment compari-
sons so that the strength of randomized controlled trials
may be partially preserved [3e6]. However, the validityConflict of interest: none.
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Open access under CC BY license. of indirect comparison methods is still controversial
[7e9]. A recent study found that a significant inconsistency
between direct and indirect evidences might be more prev-
alent than those previously estimated [10].
The validity of indirect treatment comparisons is depen-
dent on some basic assumptions [1,11]. For the indirect
comparison of interventions B and C based on a common
comparator A, the similarity assumption requires that the
average relative effect estimated by one set of trials (AvB
trials) is generalizable to the other set of trials (AvC trials).
To combine the results of direct and indirect comparisons
(i.e., mixed treatment comparisons), an additional evidence
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Key findings
 Trial similarity and evidence consistency scores
obtained using the assessment framework were
not associated with statistically significant incon-
sistency between direct and indirect estimates.
What this adds to what was known?
 Trial similarity and evidence consistency should be
appropriately assessed in any indirect or mixed
treatment comparisons. This study evaluated a Trial
Similarity and Evidence Consistency Assessment
framework for assessing key assumptions underly-
ing the validity of indirect comparisons.
What is the implication and what should change
now?
 The overall trial similarity and evidence consis-
tency scores are unlikely to be sufficiently accurate
for predicting inconsistency between direct and in-
direct estimates. However, the assessment frame-
work proposed in this study can be a useful tool
for identifying between-trial differences that may
threaten the validity of indirect treatment
comparisons.consistency assumption is required, which assumes that the
evidence from different sources is sufficiently consistent.
Imbalance in the distribution of relative treatment effect
modifiers across the trials involved in the indirect and
mixed treatment comparisons will violate the similarity
and consistency assumptions [1,12].
It has been recommended that the trial similarity and ev-
idence consistency should be appropriately assessed in any
indirect or mixed treatment comparisons [1,2]. However,
practical methods for assessing clinical similarity and evi-
dence consistency across trials have not been tested. This
study aimed to propose and empirically evaluate an assess-
ment framework for assessing key assumptions related to
the exchangeability of evidence in indirect comparisons.
We hypothesized that the assessment framework could be
used to predict the observed discrepancy between direct
and indirect comparisons. In this article, we report the over-
all findings based on a sample of 94 Cochrane Systematic
Reviews (CSRs), followed by a detailed case study.2. Methods
The methods for the identification of relevant CSRs have
been described in a previous publication [10]. Briefly, we
searched the Cochrane Database of Systematic Reviewsto identify CSRs that provided data to compare two com-
peting interventions (B and C) by both direct and indepen-
dent indirect comparisons based on a common comparator
(A). The basic characteristics of the 94 CSRs included in
this study are shown in Table S1 (see at www.jclinepi.com).2.1. Data extraction
From the included CSRs, one reviewer initially extracted
the following data into an evidence table: relevant trials for
direct or indirect comparisons, the outcome of interest, and
event rates in the common comparator arms (Table S2; see
at www.jclinepi.com). Then, two reviewers used the
evidence table to extract data from three sets of trials
(BvC trials for direct comparison, and AvB and AvC trials
for indirect comparison) in each of the included CSR. We
estimated the typical ranges of important characteristics
of patients (age, sex ratio, and severity); interventions (dos-
ages or intensity); outcome measures; and length of follow-
up separately for the BvC, AvB, and AvC trials. A narrative
summary was provided about the similarities and differ-
ences between these sets of trials.
We relied on study tables presented in CSRs to obtain
the data required. The full publication of the trials was used
when necessary to check or supplement data retrieved from
CSRs. The data extraction was independently conducted in
duplicate by the two reviewers. Any disagreement was re-
solved by discussion and/or by the involvement of a third
reviewer. To achieve blinded assessment, the two indepen-
dent reviewers were not aware of the results of indirect
comparisons, and relevant data plots were removed from
the CSRs during data extraction.2.2. Similarity and consistency assessment
In the assessment of clinical similarity between trials in
indirect comparisons, the first key question we asked was
‘‘are there any noticeable differences between the two sets
of trials in terms of trial participants, interventions, out-
comes measured, and other study level variables’’? If so,
then we considered the next question: ‘‘is the relative effect
likely to be different because of the observed differences
between AvB and AvC trials’’? To facilitate answering
these two important but judgemental questions, we de-
signed a Trial Similarity and Evidence Consistency Assess-
ment (TSECA) framework.
Our TSECA framework consists of four components: the
aforementioned evidence table, a clinical trial similarity as-
sessment (TSA), a quality similarity assessment (QSA), and
an evidence consistency assessment (ECA). The TSA and
QSA relate to the validity of adjusted indirect comparisons,
whereas the ECA relates to the validity of mixed treatment
comparisons.
Using data compiled in the evidence table, two re-
searchers independently assessed the clinical similarity of
the two sets of trials (AvB and AvC) in the indirect
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ilarity were conveyed as a TSA score ranging from one
(very low, with severe concerns) to five (very high similar-
ity, with no concern), using the TSA sheet for assessing
trial clinical similarity (Table S3; see at www.jclinepi.
com). The development of the scales aimed to elicit per-
ceived trial similarity based on the main characteristics of
study participants, interventions (including control), and
outcome measures, aspects that are recommended for clin-
ical heterogeneity investigation in meta-analysis [13].
The quality of trials was scored from one (very low) to
five (very high), according to randomization method, allo-
cation concealment, blinding of patients and outcome as-
sessors, and reported dropouts (Table S4; see at www.
jclinepi.com) [14]. The quality scores of multiple trials
were weighted by the number of patients in each trial to
calculate an average quality score. When a set of trials is
more or less biased than another set of trials, the adjusted
indirect comparison may underestimate or exaggerate the
relative effect [7]. Therefore, the quality similarity (QSA
score) was measured by comparing the average quality
scores of the two trial sets.
Using a method similar to the TSA described previously,
ECA was conducted to examine consistency of trial evi-
dence between direct and indirect estimates. The ECA
was also based on overall characteristics of trial partici-
pants, interventions compared, and outcomes measured
(Table S5; see at www.jclinepi.com). For example, inter-
ventions B and C in the two sets of indirect comparison tri-
als (i.e., AvB and AvC trials) should be consistent with
interventions B and C in the head-to-head comparison trials
(BvC trials). The results of ECAwere also scored from one
(very low) to five (very high consistency). In principle, the
total ECA score should be equal to or lower than the TSA
score.
The assessment of trial similarity and evidence consis-
tency is inevitably a subjective process. The assessment
was conducted by two reviewers independently and any
disagreement was discussed at weekly project meetings
with the involvement of other team members. However,
the disagreement in the assessment scores between the
two assessors was allowed to remain even after the discus-
sion. A simple average score was calculated when the final
scores were different between the two assessors.2.3. Data analysis methods
The interassessor reliability was investigated using the
BlandeAltman method [15]. The construct validity of the
assessment of trial similarity was tested by investigating
whether similarity scores are associated with the extent of
discrepancy between the direct and indirect estimates. We
used the method by Bucher et al. [4] to conduct indirect
comparisons, and estimated statistical inconsistency
between the direct and indirect comparisons. The method
used to calculate the quantitative discrepancy betweendirect and indirect estimates has been previously described
[10,16]. It was hypothesized that trial dissimilarity or evi-
dence inconsistency as measured by the TSECA framework
may be associated with greater discrepancy between the
direct and indirect comparisons.3. Results
3.1. Main findings
The results of the similarity and consistency assess-
ments, as well as the main characteristics of the included
CSRs, are presented in Table S1 (see at www.jclinepi.com).
The differences between the two assessors were visually
distributed around zero (Figure S1; see at www.jclinepi.
com). One reviewer tended to give a higher score than an-
other for the clinical similarity (mean difference5 0.29;
95% confidence interval [CI]5 0.17e0.42) and consis-
tency (mean difference5 0.28; 95% CI5 0.16e0.41) of
outcome measures (Figure S2; see at www.jclinepi.com).
In addition, a higher score was given by the same reviewer
to the consistency of interventions. There was no significant
difference in the quality similarity score between the two
reviewers.
The overall TSA score was symmetrically distributed
(median5 3.83; range5 2.56e4.79; Fig. 1). Of the three
clinical components, the participant similarity scores (me-
dian5 3.42) were on average lower than the intervention
and outcome similarity scores (median5 4.17 and 4.00, re-
spectively). With a median score of 4.24, the distribution of
QSA scores is negatively skewed. Note that a high quality
similarity score may be achieved if the two sets of trials
were similarly good or poor. The distribution of ECA
scores is similar to that of TSA scores (Fig. 1).
Statistically significant discrepancy between direct and
indirect estimates (P! 0.05) was observed in 16 of the
94 CSRs included. The proportion of significant discrep-
ancy was similar when studies were groups according to
similarity or consistency scores (Table 1). There was no
association between any assessment scores and the discrep-
ancies between direct and indirect estimates, using data
from 83 CSRs in which odds ratio (OR) could be used as
the outcome statistic (Fig. 2).
3.2. A case study
The case study used data from a Cochrane review that
compared topical azelaic acid and topical metronidazole in
patients with rosacea [17]. A single direct comparison trial
found that topical azelaic acid was more effective than top-
ical metronidazole (OR5 0.55; 95% CI5 0.33e0.91) [18].
However, the adjusted indirect comparison based on six
trials suggested that azelaic acid was less efficacious than
metronidazole (OR5 2.68; 95% CI5 1.31 to 5.46; Fig. 3).
In the assessment of similarity and consistency across
trials, we observed some differences between trials in
Fig. 1. Distribution of similarity and consistency assessment scores.
Table 1. Similarity/consistency scores and statistically significant
inconsistency between direct and indirect estimates
Trial similarity scores and
other variables (grouped
by quantile points)
N (%) with
significant
inconsistency
P-value
for difference
between subgroups
Average trial clinical similarity score
3.51 4/25 (16.0) 0.114
O3.51 & 3.84 2/22 (9.1)
O3.84 & 4.12 8/25 (32.0)
O4.12 2/22 (9.1)
Trial quality similarity score
3.67 3/23 (13.0) 0.891
O3.67 & 4.235 4/24 (16.7)
O4.235 & 4.62 4/24 (16.7)
O4.62 5/23 (21.7)
Evidence consistency scores
3.36 3/24 (12.5) 0.831
O3.36 & 3.645 4/23 (17.4)
!3.645 & 3.90 5/22 (22.7)
O3.90 4/25 (16.0)
Minimal similarity or consistency scores
1.75 6/31 (19.4) 0.734
O1.75 & 2.00 5/32 (15.6)
O2.00 & 2.25 5/26 (19.2)
O2.25 0/5 (0.0)
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to assess subjective outcomes, and length of follow-up
(Table S6eS9; see at www.jclinepi.com). However, the im-
portance of these observed differences were sometimes in-
terpreted differently by the two assessors. The average TSA
score was 3.85, the QSA score was 4.41, and the ECA score
was 3.63. These overall scores were not different from
those of the other cases without significant inconsistency
between the direct and indirect estimates, and thus could
not explain the striking inconsistency observed in this case.
Fig 4 shows pooled event rates in single arms of differ-
ent sets of trials. The pooled event rate in the placebo arm
in the azelaic acid trials was considerably lower than that in
the metronidazole trials (48% vs. 74%). This difference rai-
ses doubt about the similarity of patients between the twosets of trials in the indirect comparison. Patients included
in the early metronidazole trials seemed less likely to have
spontaneous improvement, as compared with those in the
azelaic acid trials. However, patients in the placebo-
controlled trials responded similarly to the two active treat-
ments as those in the direct comparison trial (31% vs. 29%
to azelaic acid and 45% vs. 50% to metronidazole). There-
fore, the difference in the placebo effect between the two
sets of trials is likely an important effect modifier.
The direct comparison trial compared a novel, newly de-
veloped 15% gel formulation of azelaic acid and 0.75%
metronidazole gel [18]. The authors received funding from
the manufacturer of the new azelaic acid gel. The newly de-
veloped azelaic acid gel in the direct comparison may be
different from that used in the placebo-controlled trials.
In addition, metronidazole gel was used in the direct com-
parison trial, whereas metronidazole cream was used in the
placebo-controlled trials. However, it is unclear whether
these differences in the treatments modified the relative
treatment effects.
In summary, we were able to identify some differences
in participants, interventions, and outcome measures be-
tween trials using the TSECA framework. However, it is
difficult to decide the importance of the observed differ-
ences in terms of effect modifications. After further detailed
consideration, we conclude that the indirect comparison
may not be valid in this case owing to the different response
to placebo between the two sets of trials in the indirect
comparison. In addition, the result from the direct compar-
ison may suffer from the optimum bias that may be present
when new drugs are compared with old drugs in direct
comparison trials [19].
Fig. 2. Similarity and consistency scores against absolute discrepancy
(in log ratio of odds ratios) between direct and indirect estimates.
Fig. 3. TAA vs. TM for rosacea (outcome: lack of improvement accord-
ing to physician’s global evaluation). TAA, topical azelaic acid; TM,
topical metronidazole.
Fig. 4. Topical azelaic acid vs. topical metronidazole for rosacea:
response by study arms.
188 T. Xiong et al. / Journal of Clinical Epidemiology 66 (2013) 184e1914. Discussion
A recent study based on data from published systematic
reviews (including the CSRs used in this study) reported
that the inconsistency between direct and indirect compar-
isons was statistically significant in 14% of the cases, which
is more prevalent than those previously observed [10].
Based on theoretical considerations, we have hypothesized
that the assessment of trial similarity and evidence consis-
tency may predict the significant inconsistency between
direct and indirect comparisons. However, this hypothesis
was not confirmed by the findings from this study. We
found no relationship between the assessment scores and
the discrepancy between the direct and indirect compari-
sons. This result may be explained by the following
reasons:
 Assessors’ insufficient knowledge and understanding
of clinical topics,
 Inadequate information available from the CSRs and
primary studies, Inadequate sensitivity and/or specificity of the tools,
and
 Difficulties in identifying effect modifiers.4.1. Insufficient understanding of the clinical topics
The two assessors who assessed the similarity and consis-
tency have backgrounds of medical- and health-related
189T. Xiong et al. / Journal of Clinical Epidemiology 66 (2013) 184e191training. However, a large number of Cochrane reviews on
a wide range of clinical topics were included. For each
included case, they had only 2e3 days on average to com-
plete the assessment forms, and to make subjective judge-
ments about trial similarity and evidence consistency.
Because of the time restriction and clinical diversities, their
understanding of the relevant clinical topics was likely to be
superficial or inadequate in many cases. The two assessors
were able to identify some possible effect modifiers. For
example, they noticed difference in placebo response rate
between trials in the case study (Table S7; see at www.
jclinepi.com). Clinical experts may help the identification
of potential treatment effect modifiers and for the interpreta-
tion of observed differences. Further research is required to
evaluate the involvement of clinical content specialists in the
assessment of trial similarity and evidence consistency.
4.2. Inadequate information available
The assessment was based mainly on data extracted
from study tables in the included CSRs. Information pre-
sented in study tables in some CSRs may not be adequate
for an appropriate assessment of trial similarity and evi-
dence consistency. In addition, assessors were blinded to
the quantitative results of the relevant meta-analyses to
avoid possible bias in the subjective assessment process.
4.3. Limitations of the assessment tools
The assessment of similarity and consistency is a process
of subjective judgment based mainly on data from study ta-
bles in the included CSRs. The difference in overall similar-
ity and consistency scores between the two assessors was
statistically significant. Although the two assessors were able
to identify similar differences in participants, interventions,
and outcomes, they often disagreed on the perceived impact
of the observed differences on the effect estimates of relative
effectiveness. In some cases, the disagreement remained
even after discussion, as is shown in the case study. There-
fore, the tools proposed may not be sufficiently reliable.
The assessment tools used may have inadequate sensitiv-
ity and specificity. A large number of variables were con-
sidered in the assessment of trial similarity and evidence
consistency. Difference in only one variable may be suffi-
cient to violate the trial similarity or evidence consistency
assumptions. Therefore, an average score by pooling sub-
scores of many variables may conceal the key threat(s) to
the validity of indirect comparisons. However, in further
exploratory analyses, we again failed to find any clear asso-
ciation between the minimum items-specific assessment
scores and the observed inconsistency between direct and
indirect estimates.
4.4. Difficulties in identifying effect modifiers
The validity of the adjusted indirect comparison depends
on the trial similarity in terms of modifiers of relativetreatment effects, an issue related to external validity or
generalizability of trial results. For an adjusted indirect
comparison of BvC to be valid, the result from AvB trials
should be generalizable to patients in AvC trials, and the
result of AvC trials should be generalizable to patients in
AvB trials. If the effect modifiers are distributed unevenly
among trials, the generalizability of results between the
trials will be problematic.
The term effect modifier and moderator are often consid-
ered synonymous. Kraemer et al. [20] defined ‘‘moderators
of treatment outcomes’’ as ‘‘a pretreatment or baseline vari-
able that identifies subgroups of patients within the popula-
tion who have different effect size.’’ More generally, any
variables that affect the relative effect of a treatment, or re-
lated to external validity, are relevant for the assessment of
trial similarity and evidence consistency. Rothwell [21]
provided a long list of possible factors that may affect the
external validity, including study settings, selection of pa-
tients, intervention characteristics, outcome measures, and
follow-up.
It is important to note that the same factors may be re-
sponsible for heterogeneity in pairwise meta-analysis, in-
valid adjusted indirect comparison, and inconsistency
between direct and indirect estimates [22]. The frequency
of treatmenteeffect modification was estimated to be at
least 10%, based on empirical observations of significant
heterogeneity in pairwise meta-analyses [23]. The presence
of heterogeneity in pairwise meta-analyses may also lead to
an imbalance in the distribution of effect modifiers across
different sets of trials for indirect and mixed treatment com-
parisons, which is more likely when the number of studies
in a network meta-analysis is small. For example, the inclu-
sion of small numbers of trials is associated with the risk of
statistically significant inconsistency between direct and
indirect comparisons [10].
Although quantitative methods are available to investi-
gate heterogeneity across studies in meta-analysis and the
inconsistency between direct and indirect comparisons,
the assessment of trial similarity for adjusted indirect com-
parison is mainly based on subjective judgment [24]. Some
recent studies attempted to improve the validity of indirect
and mixed treatment comparisons by adjusting for study-
level covariables [25e27]. The meta-regression methods
have often limited use because of insufficient number of
available studies.
In most circumstances, we may be able to identify some
differences in patient characteristics, interventions, and out-
comes measured between trials. However, the observed
between-trial differences may not necessarily modify rela-
tive treatment effects [11]. A predictor of the outcome
may have similar effect on patients in the intervention
group and patients in the control group so that the relative
treatment effect is not affected. Generally, there is a lack of
adequate clinical understanding and empirical evidence on
plausible effect modifiers, which may be the main cause of
the poor predictability of the assessment scores.
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We used the case study to demonstrate the actual use of
the TSECA framework, and to conduct further detailed,
exploratory investigation of trial similarity and evidence
consistency. In the case study, the quantitative inconsis-
tency between the direct and indirect estimates could not
be explained by corresponding similarity and consistency
assessment scores. The use of the TSECA framework en-
abled us to identify some between-trial differences in par-
ticipants, interventions, and outcome measures, although
we were uncertain about the impact of the most-observed
between-trial differences. After further detailed consider-
ation, we concluded that the indirect comparison may be
invalid because of different baseline risks (as reflected by
the event rate in the placebo arms) between the two sets
of trials in the indirect comparison. The difference in the
baseline risk may be caused by an imbalance in the distri-
bution of certain prognostic variables across trials. The
indirect and mixed treatment comparisons will be invalid
if any of these prognostic variables are also known or
unknown modifiers of the relative treatment effect [12].
Therefore, the case study suggested that the comprehensive
assessment of trial similarity and evidence consistency can
provide important evidence on the validity of the indirect
and mixed treatment comparisons.5. Conclusions
The assessment of trial similarity and evidence consis-
tency for indirect or mixed treatment comparisons seeks
to answer two key questions. The first question is whether
there are considerable differences in participants, interven-
tions, outcome measures, and the risk of bias between dif-
ferent sets of trials. The second question is whether the
relative treatment effect may have been modified by any
of the observed between-trial differences. The TSECA
framework evaluated in this study may be helpful for an-
swering the first question. Although any overall trial simi-
larity or evidence consistency scores are unlikely to be
accurate enough for predicting the inconsistency between
direct and indirect estimates, we can use this framework
to systematically and explicitly collate relevant evidence
for identifying between-trial differences that may threaten
the validity of indirect or mixed treatment comparisons.Acknowledgments
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